Company to Utilize Kofinas's, Janiak's MIPs Technology

Link Plus Corporation, a biotechnology company located in Columbia, Md., has announced that it has formed a subsidiary called Link Plus BioTech, Inc. to focus on public health related applications of Molecularly Imprinted Polymers (MIPs)* for the specific detection, binding, and separation of viruses using technology created by Fischell Department of Bioengineering Professor Peter Kofinas and Materials Science and Engineering graduate student Daniel Janiak (who is advised by Kofinas) at the Clark School's Functional Macromolecular Laboratory. The creation of Link Plus BioTech results from an exclusive license agreement with the University of Maryland. Kofinas will serve as the subsidiary's Chief Technology Officer.

Janiak and Kofinas' technology takes the form of a highly absorbent, water-insoluble polymer hydrogel that resembles firm gelatin. The gel is imprinted with a specific virus' shape. When molecules of that target virus are filtered though the gel, they–and only they–fit snugly into the imprint cavities and are trapped.

Kofinas is widely regarded as the leading research scientist in the field of applying MIPs technology to biological threats. He and his team have successfully detected viruses using the MIPs technology and commercially available sensor systems. Future research by Link Plus BioTech will expand on the breadth of viruses which can be detected and extend the technology to a myriad of antibiotic-resistant bacteria, including MRSA.

"The creation of Link Plus BioTech allows us to establish a sharp focus on the application of MIPs for public health related needs," said Robert L. Jones, Jr., CEO of Link Plus Biotech in a recent press release. He explained that devices could be developed consisting of custom synthesized molecularly imprinted polymers that are compatible with dialysis, hemodialysis, or blood analysis systems already available in hospitals and clinics, easily and cost-effectively converting them into virus systems capable of the direct removal of viruses from the bloodstream in patients with HIV, Hepatitis B, Hepatitis C, or other infections. While not a cure, it should reduce the viral load (concentration of a virus) in the patients' bodies and aid in the treatment of these diseases.

The MIPs technology could also lower the cost of vaccine production by quickly and inexpensively filtering the inactive virus particles needed to create a vaccine from the biomasses in which they reside.